I.v. cocaine induces rapid, transient excitation of striatal neurons via its action on peripheral neural elements: single-cell, iontophoretic study in awake and anesthetized rats.
Cocaine's (COC) direct interaction with the dopamine (DA) transporter is usually considered the most important action underlying the psychomotor stimulant and reinforcing effects of this drug. However, some physiological, behavioral and psycho-emotional effects of COC are very rapid and brief and they remain intact during DA receptor blockade, suggesting possible involvement of peripheral non-DA neural mechanisms. To assess this issue, single-unit recording with microiontophoresis was used to examine changes in impulse activity of dorsal and ventral striatal neurons to i.v. COC (0.25-0.5 mg/kg) in the same rats under two conditions: awake with DA receptor blockade and anesthetized with urethane. In the awake preparation approximately 70% striatal neurons showed rapid and transient (latency approximately 6 s, duration approximately 15 s) COC-induced excitations. These effects were stronger in ventral than dorsal striatum. During anesthesia, these phasic effects were fully blocked and COC slowly decreased neuronal discharge rate. Cocaine-methiodide (COC-M), a derivative that cannot cross the blood-brain barrier, also caused phasic excitations in the awake, but not anesthetized condition. In contrast to regular COC, COC-M had no tonic effect on discharge rate in either preparation. Most striatal neurons that were phasically excited by both COC forms also showed short-latency excitations during tail-touch and tail-pinch in the awake preparation, an effect strongly attenuated during anesthesia. Finally, most striatal neurons that in awake conditions were phasically excited by somato-sensory stimuli and COC salts were also excited by iontophoretic glutamate (GLU). Although striatal neurons were sensitive to GLU in both preparations, the response magnitude at the same GLU current was higher in awake than anesthetized conditions. These data suggest that in awake animals i.v. COC, like somato-sensory stimuli, transiently excites striatal neurons via its action on peripheral neural elements and rapid neural transmission. While the nature of these neuronal elements needs to be clarified using other analytical techniques, they might involve voltage-gated K(+) and Na(+) channels, which have a high affinity for COC and are located on terminals of visceral sensory nerves that densely innervate peripheral vessels. Therefore, along with direct action on specific brain substrates, central excitatory effects of COC may occur via indirect action, involving afferents of visceral sensory nerves and rapid neural transmission. By providing a rapid sensory signal and triggering transient neural activation, such a peripherally triggered action might play a crucial role in the sensory effects of COC, thus contributing to learning and development of drug-taking behavior.
Kiyatkin
E A
EA
Behavioral Neuroscience Branch, National Institute on Drug Abuse-Intramural Research Program, National Institutes of Health, DHHS, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA. ekiyatki@intra.nida.gov
Brown
P L
PL
D000200:Action Potentials / Q000187:drug effects; D000704:Analysis of Variance; D000758:Anesthesia; D000818:Animals; D003042:Cocaine / Q000008:administration & dosage*; D003342:Corpus Striatum / Q000166:cytology*; D018765:Dopamine Uptake Inhibitors / Q000008:administration & dosage*; D004333:Drug Administration Routes; D007275:Injections, Intravenous / Q000379:methods; D007478:Iontophoresis / Q000379:methods; D008297:Male; D009474:Neurons / Q000187:drug effects*; D051381:Rats; D020318:Rats, Long-Evans; D014851:Wakefulness / Q000502:physiology*
D018765:Dopamine Uptake Inhibitors; D003042:Cocaine
Brain Res. 1999 Mar 20;822(1-2):88-106
10082887
J Neurosci. 1999 May 1;19(9):3594-609
10212318
J Neurophysiol. 1999 May;81(5):2243-52
10322063
Synapse. 2000 Mar 1;35(3):238-42
10657032
Neuroscience. 2000;98(4):729-41
10891616
Neuroscience. 2001;102(3):565-80
11226694
Biochem Pharmacol. 1975 Apr 15;24(8):847-52
1125084
Mol Pharmacol. 2001 May;59(5):1069-76
11306689
J Pharmacol Exp Ther. 2001 Oct;299(1):220-6
11561083
Pharmacol Biochem Behav. 1979 Dec;11(6):669-72
119976
J Neurophysiol. 2002 Jul;88(1):300-5
12091555
Behav Brain Res. 2002 Dec 2;137(1-2):27-46
12445714
Pharmacology. 2003 May;68(1):49-56
12660479
J Pharmacol Exp Ther. 1992 Nov;263(2):757-61
1359115
J Pharmacol Exp Ther. 1992 Nov;263(2):734-41
1432699
Eur J Neurosci. 2004 Nov;20(10):2838-42
15548229
Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10023-8
16006505
Eur J Neurosci. 2005 Aug;22(4):930-8
16115216
J Membr Biol. 2005 Apr;204(3):129-36
16245035
Neuroscience. 2006;138(1):257-80
16377093
Mol Cells. 2005 Dec 31;20(3):315-24
16404144
Basic Clin Pharmacol Toxicol. 2006 May;98(5):510-7
16635111
BMC Neurosci. 2006 Jun 08;7:46
16762059
Brain Res. 1991 Apr 19;546(2):287-96
1676928
Neuropsychopharmacology. 2006 Nov;31(11):2341-8
16855534
Eur J Neurosci. 2006 Aug;24(3):917-24
16930419
Eur J Neurosci. 2006 Aug;24(4):1182-92
16930444
Mol Neurobiol. 2006 Aug;34(1):1-26
17003519
Neuropsychopharmacology. 2007 May;32(5):1141-58
17019407
Neuropsychopharmacology. 2007 Jun;32(6):1232-41
17151599
Eur J Pharmacol. 1991 Jun 6;198(2-3):203-5
1864307
Brain Res. 1991 Apr 19;546(2):297-309
2070264
J Pharmacol Exp Ther. 1990 Oct;255(1):154-60
2213551
NIDA Res Monogr. 1989;95:146-51
2561820
Int J Neurosci. 1989 Jan;44(1-2):111-33
2562051
Psychiatry Res. 1989 Feb;27(2):117-25
2652168
Addict Biol. 1998 Apr;3(2):189-96
26734823
Science. 1987 Sep 4;237(4819):1219-23
2820058
Psychopharmacology (Berl). 1986;90(1):142-3
2876452
J Pharmacol Exp Ther. 1988 Aug;246(2):466-71
2900325
Oral Surg Oral Med Oral Pathol. 1979 Oct;48(4):292-7
291855
Pharmacol Biochem Behav. 1987 Feb;26(2):453-61
3033700
Int J Neurosci. 1988 Sep;42(1-2):21-43
3209370
Psychol Rev. 1987 Oct;94(4):469-92
3317472
J Neurosci. 1988 Jan;8(1):100-12
3339402
Prog Neuropsychopharmacol Biol Psychiatry. 1987;11(4):345-64
3423267
Life Sci. 1987 Mar 16;40(11):1099-111
3821374
Br J Anaesth. 1985 Oct;57(10):1006-11
4041306
Arch Int Pharmacodyn Ther. 1971 Jan;189(1):198-208
5130150
Psychopharmacology (Berl). 1982;78(3):204-9
6296898
Brain Res. 1983 Oct;287(2):139-71
6357356
Psychopharmacology (Berl). 1980 Feb;67(2):189-94
6768094
Brain Res. 1983 Jan 10;258(2):217-28
6824912
Pharmacol Biochem Behav. 1983 May;18(5):711-6
6856646
Prog Neurobiol. 1980;14(2-3):69-97
6999537
Brain Res. 1982 Jan 28;232(1):29-39
7055709
J Neurosci. 1981 Aug;1(8):887-900
7346593
Brain Topogr. 1995 Spring;7(3):209-16
7599020
Brain Res Brain Res Rev. 1995 Jan;20(1):91-127
7711769
Neuroscience. 1995 Feb;64(3):599-617
7715774
J Neurosci. 1994 Dec;14(12):7735-46
7996208
J Physiol. 1994 Jan 15;474(2):233-43
8006810
Prog Brain Res. 1993;99:277-97
8108553
J Neurosci. 1994 Mar;14(3 Pt 1):1224-44
8120621
Neurosci Lett. 1993 Dec 24;164(1-2):175-8
8152597
J Neurosci Methods. 1993 Apr;47(1-2):53-9
8321014
Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2212-6
8460124
J Neurosci. 1996 May 15;16(10):3459-73
8627379
J Neurophysiol. 1996 Jan;75(1):142-53
8822548
Physiol Behav. 1996 Jan;59(1):109-15
8848468
Synapse. 1996 Nov;24(3):233-9
8923663
Synapse. 1998 Feb;28(2):111-6
9450511
J Neuropsychiatry Clin Neurosci. 1998 Spring;10(2):148-59
9608403
Psychopharmacology (Berl). 1978 Apr 14;57(1):13-20
96463
J Neurosci. 1998 Nov 1;18(21):9055-68
9787009
Eur J Pharmacol. 1998 Dec 18;363(2-3):147-52
9881582
J Cardiovasc Pharmacol. 1999 Jan;33(1):36-42
9890394